Skip to main content
MedPathMedPath Home
Clinical Trials/TCTR20200128004
TCTR20200128004
Completed
Phase 2

Effects of mineralocorticoid receptor agonist on intradialytic hypotension: an open-label, randomized crossover study

ampang hospital0 sites10 target enrollmentJanuary 28, 2020
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsIntradialytic hypotensionMineralocorticoid receptor agonist

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Intradialytic hypotension
Sponsor
ampang hospital
Enrollment
10
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 28, 2020
End Date
October 31, 2020
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
ampang hospital

Eligibility Criteria

Inclusion Criteria

  • •ESRD patients (defined by Kidney Disease Initiative Global Outcome (KDIGO)
  • •Guideline 2012\) requiring chronic hemodialysis
  • •\- Hemodialysis vintage more than 3 months
  • •\- Hemodialysis with 2 sessions per week
  • •\- History of intradialytic hypotension at least 30% of their dialysis sessions during the
  • •past 3 months

Exclusion Criteria

  • •\- Active cardiac, pulmonary or hepatobiliary tract disease
  • •\- Active infection or sepsis
  • •\- Systemic fungal infection
  • •\- Require ultrafiltration more than 4L per session
  • •\- Active malignancy
  • •\- Prior treatment with fludocortisone in past 4 weeks
  • •\- Contraindication to fludocortisone

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Effect of spironolactone on ischemia reperfusion injury in renal transplant recipientsIschemia reperfusion injuryCirculatory System
ISRCTN01577227Mexican Council of Science and Technology (Consejo Nacional de Ciencia y Tecnología CONACyT) (Mexico)60
Completed
Phase 2
Effects of mineralocorticoid receptor antagonist on intradialytic hypertension: a multicenter, double-blind, randomized crossover studyIntradialytic hypertensionSpironolactoneMineralocorticoid receptor antagonist
TCTR20200604013ampang hospital49
Completed
Not Applicable
The effect of a mineralocorticoid receptor antagonist eplerenone on morning home BP in drug-resistant hypertensiodrug-resistant morning hypertension
JPRN-UMIN000014186Jichi Medical University School of Medicine100
Completed
Not Applicable
Effects of mineralocorticoid receptor antagonists on sex hormones and body composition in patients with primary aldosteronismPrimary aldosteronism
JPRN-UMIN000037657Tokyo Women's Medical University Hospital100
Active, not recruiting
Phase 1
Effects of mineralocorticoid receptor stimulation on cognitive bias and social cognition in patients with major depression and healthy controls: what’s the role of NMDA receptors?depressed patients and healthy control subjectsTherapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
EUCTR2014-005239-15-DECharité - Universitätsmedizin Berlin232